Caption Management’s Blueprint Medicines BPMC Stock Holding History

Caption Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,000	Closed	-$727K	–	1462
2025 Q1	$620K	Buy	+7,000	New	+$683K	0.01%	1044
2024 Q1	–	Sell	-1,834	Closed	-$157K	–	1229
2023 Q4	$169K	Buy	+1,834	New	+$119K	﹤0.01%	1130
2022 Q3	–	Sell	-24,000	Closed	-$1.21M	–	1509
2022 Q2	$1.21M	Buy	+24,000	New	+$1.41M	0.02%	815
2021 Q4	–	Sell	-24,291	Closed	-$2.54M	–	1610
2021 Q3	$2.5M	Buy	+24,291	New	+$2.26M	0.03%	680
2020 Q2	–	Sell	-22,000	Closed	-$1.29M	–	946
2020 Q1	$1.29M	Buy	+22,000	New	+$1.42M	0.07%	340
2019 Q4	–	Sell	-50,000	Closed	-$3.67M	–	830
2019 Q3	$3.67M	Buy	+50,000	New	+$4.32M	0.19%	144
2019 Q2	–	Sell	-18,000	Closed	-$1.49M	–	664
2019 Q1	$1.44M	Buy	+18,000	New	+$1.33M	0.08%	288

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Caption Management's BPMC Position: Q2 2025 in Review

Caption Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 7,000 shares — an estimated $727K sold.

Caption Management first reported a position in BPMC in Q1 2019 and held it in 7 quarters. The position peaked at $3.67M in Q3 2019. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Caption Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Caption Management sold 7,000 Blueprint Medicines shares in Q2 2025, an estimated $727K.
Caption Management first reported a position in Blueprint Medicines in Q1 2019 and held it in 7 quarters.
Caption Management's Blueprint Medicines position peaked at $3.67M in Q3 2019.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.